Cite
Liu X, Yue Z, Cao Y, et al. Graft-Versus-Host Disease-Free Antitumoral Signature After Allogeneic Donor Lymphocyte Injection Identified by Proteomics and Systems Biology. JCO Precis Oncol. 2019;3doi: 10.1200/po.18.00365.
Liu, X., Yue, Z., Cao, Y., Taylor, L., Zhang, Q., Choi, S. W., Hanash, S., Ito, S., Chen, J. Y., Wu, H., & Paczesny, S. (2019). Graft-Versus-Host Disease-Free Antitumoral Signature After Allogeneic Donor Lymphocyte Injection Identified by Proteomics and Systems Biology. JCO precision oncology, 3. https://doi.org/10.1200/po.18.00365
Liu, Xiaowen, et al. "Graft-Versus-Host Disease-Free Antitumoral Signature After Allogeneic Donor Lymphocyte Injection Identified by Proteomics and Systems Biology." JCO precision oncology vol. 3 (2019). doi: https://doi.org/10.1200/po.18.00365
Liu X, Yue Z, Cao Y, Taylor L, Zhang Q, Choi SW, Hanash S, Ito S, Chen JY, Wu H, Paczesny S. Graft-Versus-Host Disease-Free Antitumoral Signature After Allogeneic Donor Lymphocyte Injection Identified by Proteomics and Systems Biology. JCO Precis Oncol. 2019;3. doi: 10.1200/po.18.00365. Epub 2019 May 23. PMID: 31406955; PMCID: PMC6690359.
Copy
Download .nbib